fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Rinvoq (upadacitinib) receives U.S. FDA approval for giant cell arteritis – AbbVie

Written by | 24 May 2025

AbbVie announced the FDA has approved Rinvoq (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This comes after the European Commission… read more.

CHMP positive opinion for upadacitinib (Rinvoq) for the treatment of adults with giant cell arteritis – Abbvie

Written by | 20 Apr 2025

AbbVie announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (Rinvoq 15 mg, once daily) for… read more.

Abbvie to highlight early oncology pipeline and biomarker research at AARC 2025

Written by | 8 Apr 2025

AbbVie announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research (AACR) Annual Meeting, April 25-30,… read more.

Elahere (mirvetuximab soravtansine-gynx) shows consistent survival benefit in long-term analysis for certain ovarian cancer patients – AbbVie

Written by | 26 Mar 2025

AbbVie announced the final analysis of the confirmatory Phase III MIRASOL trial evaluating the efficacy and safety of Elahere  (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive… read more.

The FDA has approved Emblaveo (aztreonam and avibactam) for the treatment of complicated intra-abdominal infections (cIAI) – AbbVie

Written by | 15 Feb 2025

AbbVie announced that the FDA has approved Emblaveo (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic. It is approved in combination with… read more.

European Commisson approves Elahere (mirvetuximab soravtansine) for FRα positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer – Abbvie

Written by | 12 Dec 2024

AbbVie  announced the European Commission (EC) granted marketing authorization for Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous… read more.

FDA approves Botox Cosmetic (onabotulinumtoxinA) for temporary improvement in platysma bands in adults – Allergan/AbbVie

Written by | 1 Nov 2024

Allergan Aesthetics, an AbbVie company announced the FDA approval of Botox Cosmetic for temporary improvement in the appearance of moderate to severe vertical bands connecting the jaw and… read more.

FDA approves Vyalev (foscarbidopa + foslevodopa) subcutaneous 24-hour infusion of levodopa-based therapy for advanced Parkinson’s disease – AbbVie

Written by | 22 Oct 2024

AbbVie announced that the FDA has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations… read more.

Positive CHMP opinion for mirvetuximab soravtansine for the treatment of certain ovarian cancer – AbbVie

Written by | 6 Oct 2024

AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine… read more.

Positive CHMP opinion for mirvetuximab soravtansine (Elahere) for the treatment of certain adult ovarian cancer – AbbVie

Written by | 25 Sep 2024

AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine… read more.

FDA approves Skyrizi (risankizumab-rzaa) for ulcerative colitis, expanding AbbVie’s portfolio across inflammatory bowel disease

Written by | 4 Jul 2024

AbbVie announced the FDA has approved Skyrizi (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate… read more.

Elahere (mirvetuximab soravtansine) meets primary end point of PICCOLO trial in FR alpha-High, platinum-sensitive ovarian cancer – AbbVie

Written by | 18 Jun 2024

AbbVie announced positive topline results from the Phase II PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRalpha) positive, platinum-sensitive ovarian… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.